Efficacy of hirudin in reducing cardiovascular events in patients with acute coronary syndrome undergoing early percutaneous coronary intervention

European Heart Journal

Volumn 23, Issue 2, 2002, Pages 117-123

  Mehta, Shamir R ^a,b,f   Eikelboom, J W ^b,c   Rupprecht, H J ^d   Lewis, B S ^e   Natarajan, M K ^a,b   Yi, C ^b   Pogue, J ^b   Yusuf, S ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c ROYAL PERTH HOSPITAL   (Australia)

^d UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^e CARMEL MEDICAL CENTER   (Israel)

^f MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

Author keywords

Coronary artery disease; Hirudin; Unfractionated heparin

Indexed keywords

HEPARIN; HIRUDIN; LEPIRUDIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY THROMBOSIS; DEATH; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FIBRINOLYSIS; HEART INFARCTION; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRANSLUMINAL CORONARY ANGIOPLASTY;

ACUTE DISEASE; ANGINA, UNSTABLE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CARDIOVASCULAR DISEASES; FEMALE; HIRUDIN THERAPY; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; SYNDROME; TREATMENT OUTCOME;

EID: 0036399443     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.2001.2731     Document Type: Article

References (26)

1. Yusuf S, Flather M, Pogue J et al. Variations between countries in invasive cardiac procedures and outcomes in patients with suspected unstable angina or myocardial infarction without initial ST elevation. Lancet 1998; 352: 507-14.
2. Ellis SG, Roubin GS, King SB III et al. Angiographic and clinical predictors of acute closure after native vessel angioplasty. Circulation 1988; 77: 372-9.
3. Thel MC, Califf RM, Tardiff BE et al. Timing of and risk factors for myocardial ischemic events after percutaneous coronary intervention (IMPACT II). Am J Cardiol 2000; 85: 427-34.
4. Fuster V, Badimon L, Badimon JJ et al. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992; 326: 242-50.
5. Topol EJ. Toward a new frontier in myocardial reperfusion therapy: emerging platelet preeminence. Circulation 1998; 97: 211-18.
6. Heras M, Chesebro JH, Penny et al. Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs. Heparin vs recombinant hirudin, a specific thrombin inhibitor. Circulation 1989; 79: 657-65.
7. Heras M, Chesebro JH, Webster MW et al. Hirudin, heparin, and placebo during deep arterial injury in the pig. The in vivo role of thrombin in platelet-mediated thrombosis. Circulation 1990; 82: 1476-84.
8. Chesebro JH, Badimon L, Fuster V. Importance of antithrombin therapy during coronary angioplasty. J Am Coll Cardiol 1991; 17 (6 Suppl B): 96B-100B.
9. Popma JJ, Weitz J, Bittl JA et al. Antithrombotic therapy in patients undergoing coronary angioplasty. Chest 1998; 114: 728S-41S.
10. Boersma E, Akkerhuis KM, Theroux P et al. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: Early benefit during medical treatment only, with additional protection during percutaneous coronary intervention. Circulation 1999; 100: 2045-8.
11. Weitz JI, Hudoba M, Massel D et al. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86: 385-91.
12. Meyer BJ, Badimon JJ, Mailhac A et al. Inhibition of growth of thrombus on fresh mural thrombus. Targeting optimal therapy. Circulation 1994; 90: 2432-8.
13. Meyer BJ, Badimon JJ, Chesebro JH et al. Dissolution of mural thrombus by specific thrombin inhibition with r-hirudin. Comparison with heparin and aspirin. Circulation 1998; 97: 681-5.
14. Meyer BJ, Fernandez-Ortiz A, Mailhac A et al. Local delivery of r-hirudin by a double-balloon perfusion catheter prevents mural thrombosis and minimizes platelet deposition after angioplasty. Circulation 1994; 90: 2474-80.
15. Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: A randomised trial. Lancet 1999; 353: 429-38.
16. Rosenbaum PR. Discussing hidden bias in observational studies. Ann Intern Med 1991; 115: 901-5.
17. Joffe MM, Rosenbaum PR. Invited commentary: Propensity scores. Am J Epidemiol 1999; 150: 327-33.
18. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998; 17: 2265-81.
19. Kleiman NS, Lincoff AM, Flaker GC et al. Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes. PURSUIT Investigators. Circulation 2000; 101: 751-7.
20. Serruys PW, Herrman JP, Simon R et al. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. Helvetica Investigators. N Engl J Med 1995; 333: 757-63.
21. Bittl JA, Strony J, Brinker JA et al. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators. N Engl J Med 1995; 333: 764-9.
22. Roe MT, Granger CB, Ohman EM et al. Hirudin significantly reduces ischemic events following coronary intervention for acute coronary syndromes. J Am Coll Cardiol 2000; 35: 39A.
23. Xiao Z, Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation 1998; 97: 251-6.
24. The PRISM-PLUS Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med 1998; 338: 1488-97.
25. Topol EJ. Evolution of improved antithrombotic and antiplatelet agents: Genesis of the comparison of abciximab complications with hirulog (and back-up abciximab) events trial (CACHET). Am J Cardiol 1998; 82: 63P-68P.
26. Stone PH, Thompson B, Anderson HV et al. Influence of race, sex, and age on management of unstable angina and non-Q-wave myocardial infarction: The TIMI III registry. JAMA 1996; 275: 1104-12.